BioSpace News Archive

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the grant to one new, non-executive employee of non-qualified stock options to purchase an aggregate of 38,779 shares of the Company’s common stock at an exercise price of $4.00 per share under its Amended and Restated 2022 Inducement Equity Incentive Plan, or the Inducement Plan.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2022 results on Tuesday, November 8, 2022.

Mirum Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 52,650 shares of common stock and 26,400 restricted stock units to nine new employees under Mirum’s 2020 Inducement Plan.

The Biotechnology Innovation Organization – the world’s largest science and public advocacy organization, representing 1,000 members — announced that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO.

PROCEPT ® BioRobotics Corporation announced today that it has entered into a new five-year $52 million loan arrangement with CIBC Innovation Banking.

Morphic Therapeutic today announced the presentation of new phase 1 data from MORF-057 phase 1 studies at the United European Gastroenterology (UEG) Week 2022.

Leica Microsystems Inc., a technology leader in microscope and image analysis solutions, and S3 Medical have signed an exclusive distribution agreement.

Rocket Pharmaceuticals, Inc. today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will deliver an in-person company presentation at the 2022 Cell & Gene Meeting on the Mesa on Tuesday, October 11, at 2:30 p.m. PT in Carlsbad, CA.

STALICLA SA today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).